Startup Dossier
Phagos
French biotech pioneering phage-based therapeutics as a natural, AI-enhanced alternative to antibiotics. Phagos develops bacteriophage drugs to combat bacterial infections in veterinary medicine and has obtained the first EU authorization to market personalized phage-based treatments. Its discovery platform combines advanced microbiology with artificial intelligence to identify, design, and optimize phages for therapeutic use.
About
French biotech pioneering phage-based therapeutics as a natural, AI-enhanced alternative to antibiotics. Phagos develops bacteriophage drugs to combat bacterial infections in veterinary medicine and has obtained the first EU authorization to market personalized phage-based treatments. Its discovery platform combines advanced microbiology with artificial intelligence to identify, design, and optimize phages for therapeutic use.
Structural DNA
Legal Name
Phagos
SIREN
899702260
Founders & Team
Funding Lineage
Series A
Capagro (Lead)
€25.0M
Oct 2025
Undisclosed
0 investors
—
Aug 2024
Seed
AgFunder (Lead)
€2.4M
Sept 2022
Programs
i-Lab